Business
PacBio Completes Sale of Short-Read Sequencing Assets
MENLO PARK, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the completion of the sale of select intellectual property and other assets related to PacBio’s short-read DNA sequencing technology and related clustering, sequencing reagent, and detection technologies to Illumina, Inc. PacBio received $48.1 million in net cash proceeds from the transaction. Under the terms of the agreement, Ill
About this update from Pacific Biosciences Of California, Inc.
[{"type":"image","alt":"PacBio","displaySize":"","headline":null,"caption":"PacBio","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":263,"url":"https://media.zenfs.com/en/globenewswire.com/ca3b97d5b827c8cc2602900e245a01c9"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/nO_Xed3UYAG.Z8cezVsIzg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTM2ODtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/ca3b97d5b827c8cc2602900e245a01c9","width":300,"height":263}},"lazy":false},{"type":"text","content":"MENLO PARK, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the completion of the sale of select intellectual property and other assets related to PacBio’s short-read DNA sequencing technology and related clustering, sequencing reagent, and detection technologies to Illumina, Inc.","length":389,"tagName":"p"},{"type":"text","content":"PacBio received $48.1 million in net cash proceeds from the transaction. Under the terms of the agreement, Illumina assumed certain liabilities and granted a non-exclusive license certain intellectual property back to PacBio.","length":225,"tagName":"p"},{"type":"text","content":"“Last year, in response to challenging macroeconomic conditions, we made the strategic decision to pause development of our high-throughput short-read sequencing platform so that we can take full advantage of our innovations in the long-read sequencing market,” said Christian Henry, President and Chief Executive Officer. “This transaction further sharpens our focus and meaningfully strengthens our balance sheet. It positions us to drive adoption of our differentiated long-read sequencing platform and execute on the next phase of growth. For example, we have accelerated development of SPRQ-Nx chemistry to launch globally. SPRQ-Nx offers the most complete view of the genome at a competitive pricing structure.”","length":717,"tagName":"p"},{"type":"text","content":"The transaction closed on January 30, 2026.","length":43,"tagName":"p"},{"type":"text","content":"About PacBio","length":12,"tagName":"p"},{"type":"text","content":"PacBio (NASDAQ: PACB) is a premier life science technology company that designs, develops, and manufactures advanced sequencing solutions to help scientists and clinical researchers resolve genetically ...